Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

T Cell Types and Functions01:24

T Cell Types and Functions

1.4K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
1.4K
Inflammatory Response01:28

Inflammatory Response

5.8K
An inflammatory response is a localized, nonspecific immune reaction that occurs when a tissue is injured. It is characterized by redness, swelling, heat, and pain, which are commonly called the cardinal signs and symptoms of inflammation. Inflammation can sometimes result in a loss of function.
Inflammation can be triggered by various stimuli, such as impact, abrasion, chemical irritation, infections, and extreme hot or cold temperatures. These can damage cells and connective tissue fibers,...
5.8K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

9.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
9.2K
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

7.8K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
7.8K
The Tumor Microenvironment02:17

The Tumor Microenvironment

6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.3K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rehabilitation effect of standing bed combined with early anti-gravity running table training on ankle fracture.

Scientific reports·2024
Same author

Photodynamic Therapy Derived Personalized Whole Cell Tumor Vaccine Prevents Postsurgery Tumor Recurrence and Metastasis.

Small (Weinheim an der Bergstrasse, Germany)·2024
Same author

Repeated (<i>S</i>)-ketamine administration ameliorates the spatial working memory impairment in mice with chronic pain: role of the gut microbiota-brain axis.

Gut microbes·2024
Same author

Entropy-Enhanced Multi-Doping Strategy to Promote the Electrochemical Performance of Na<sub>4</sub>Fe<sub>3</sub>(PO<sub>4</sub>)<sub>2</sub>P<sub>2</sub>O<sub>7</sub>.

Small methods·2024
Same author

The Whitaker test: a predictive tool for evaluating the surgical efficacy of upper urinary tract reconstruction in patients carrying a nephrostomy tube after surgery.

International urology and nephrology·2024
Same author

Crosstalk between fibroblasts and immunocytes in fibrosis: From molecular mechanisms to clinical trials.

Clinical and translational medicine·2024
Same journal

Feasibility of uniportal thoracoscopic sublobar resection without chest tube drainage: a retrospective cohort study.

Frontiers in oncology·2026
Same journal

Real-world effectiveness and safety of carfilzomib, pomalidomide, and dexamethasone in relapsed/refractory multiple myeloma: a retrospective analysis from China.

Frontiers in oncology·2026
Same journal

Caregiver satisfaction with early integrated palliative care in oncology: secondary outcomes from the PALLiON cluster-RCT.

Frontiers in oncology·2026
Same journal

Intracranial mesenchymal tumor with FET::CREB fusion: a rare case report.

Frontiers in oncology·2026
Same journal

The multifaceted roles of mitochondria and their therapeutic transformation: a new perspective on triple-negative breast cancer treatment.

Frontiers in oncology·2026
Same journal

Trastuzumab emtansine versus trastuzumab plus pertuzumab for HER2-positive breast cancer with residual disease after neoadjuvant therapy: a real-world study.

Frontiers in oncology·2026
See all related articles

Related Experiment Video

Updated: Sep 2, 2025

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

3.4K

IL-6: The Link Between Inflammation, Immunity and Breast Cancer.

Juan Chen1, Yanghui Wei2, Weiqin Yang3

  • 1Department of Medicine and Rehabilitation, Tung Wah Eastern Hospital, Hong Kong, Hong Kong SAR, China.

Frontiers in Oncology
|August 4, 2022
PubMed
Summary
This summary is machine-generated.

Interleukin-6 (IL-6) plays a key role in breast cancer development and immunity. Targeting the IL-6 signaling pathway shows promise for novel cancer therapies.

Keywords:
breast cancerimmuneinflammationinterleukin-6target therapy

More Related Videos

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

8.9K
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.0K

Related Experiment Videos

Last Updated: Sep 2, 2025

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment
09:00

Characterization of Immune Cells and Proinflammatory Mediators in the Pulmonary Environment

Published on: June 24, 2020

3.4K
Visualization of IL-22-expressing Lymphocytes Using Reporter Mice
10:30

Visualization of IL-22-expressing Lymphocytes Using Reporter Mice

Published on: January 25, 2017

8.9K
Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226
08:30

Isolation of Group 2 Innate Lymphoid Cells from Mouse Nasal Mucosa to Detect the Expression of CD226

Published on: May 10, 2022

2.0K

Area of Science:

  • Oncology
  • Immunology
  • Molecular Biology

Background:

  • Breast cancer remains a significant cause of mortality in women globally.
  • Interleukin-6 (IL-6) is a crucial cytokine involved in immune responses, inflammation, and cancer pathogenesis.
  • Emerging research highlights the complex roles of IL-6 in cancer, particularly breast cancer.

Purpose of the Study:

  • To review recent studies on the role of IL-6/IL-6 receptor (IL-6R) signaling in breast cancer.
  • To explore the interplay between IL-6 mediated inflammation, immunity, and breast cancer.
  • To discuss the therapeutic potential of targeting the IL-6 pathway in breast cancer treatment.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of research on IL-6 signaling pathways in cancer.
  • Examination of data on IL-6 inhibitory antibodies and combination therapies.

Main Results:

  • IL-6 is implicated in various aspects of breast cancer, including proliferation, survival, and immune evasion.
  • IL-6 signaling pathways are critical regulators of inflammation and immunity within the tumor microenvironment.
  • Combination therapies involving IL-6 inhibitors show promising outcomes in preclinical and clinical settings.

Conclusions:

  • The IL-6/IL-6R pathway is a significant factor in breast cancer progression and immune modulation.
  • Targeting IL-6 signaling presents a viable therapeutic strategy for breast cancer.
  • Further investigation into IL-6 targeted therapies, especially in combination, is warranted for improved breast cancer treatment outcomes.